Media

Latest News

PIQUR wins the Northwest Switzerland Young Entrepreneurs’ Award 2014

November 10, 2014

PIQUR, focused on the research and development of new and innovative cancer treatments, has won the Northwest Switzerland Young Entrepreneurs’ Award On 7 November 2014, at the Congress Centre of...

Read More

Versant Ventures invests CHF 11 million in PIQUR and brings further industry expertise to the Board

April 8, 2014

Since the start of the company, PIQUR has raised total proceeds of over CHF 37 million Funds targeted to reach Phase II and proof-of-concept for lead compound PQR309 Please find...

Read More

PIQUR launches Phase I study with its lead compound PQR309 and successfully completes Series A financing round

January 21, 2014

License agreement with University of Basel extended by additional indications PIQUR Therapeutics AG, focused on the discovery and development of innovative anti-cancer drugs, has successfully completed the Series A financing...

Read More

Congratulations to Michael Hall, Winner of the first Breakthrough Prize in Life Sciences

December 13, 2013

PIQUR Therapeutics AG congratulates its Scientific Advisory Board Member, Michael Hall on winning the first Breakthrough Prize in Life Sciences. Michael N. Hall, Professor of Biochemistry at the Biozentrum of the...

Read More

PIQUR successfully closed a third seed financing round and received Eurostars grant

September 5, 2013

Board of Directors and Management Team strengthened with top experts Basel, Switzerland – PIQUR Therapeutics AG, focused on the discovery and development of innovative anti-cancer drugs, announces that is has...

Read More

Positive results of regulatory toxicology studies pave the way for first in human clinical trials

August 22, 2013

Basel, Switzerland – PIQUR Therapeutics AG, focusing on the discovery and the development of innovative anti-cancer drugs, announces today that it has successfully completed preclinical profiling and the GLP toxicology...

Read More

PIQUR secured funding to start the development of innovative anti-cancer therapies. Successful spin-off of the University of Basel

February 11, 2013

PIQUR Therapeutics AG is a targeted cancer therapy start-up company focused on the discovery and the development of innovative anti-cancer drugs. PIQUR was incorporated in August 2011 as a spin-off...

Read More

Prof. Michael N. Hall awarded 2012 Marcel Benoist Prize

September 24, 2012

Michael N. Hall, Professor at the Biozentrum of the University of Basel and Director of the Basel Signaling Alliance, received this year’s Marcel Benoist Prize – a prize sometimes called...

Read More